MetaVia Inc. (NASDAQ:MTVA – Free Report) – Equities researchers at HC Wainwright issued their FY2029 earnings per share estimates for MetaVia in a report released on Friday, March 21st. HC Wainwright analyst E. Arce anticipates that the company will earn ($5.01) per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share.
MetaVia Stock Performance
NASDAQ:MTVA opened at $1.58 on Monday. The company has a 50 day moving average price of $1.68. MetaVia has a 12 month low of $1.29 and a 12 month high of $5.30.
About MetaVia
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
See Also
- Five stocks we like better than MetaVia
- How to trade using analyst ratings
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- How to Invest in the Best Canadian Stocks
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Best Aerospace Stocks Investing
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
